Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1080-1090, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-259511
ABSTRACT
Human protein tyrosine kinases play an essential role in carcinogenesis and have been recognized as promising drug targets. By the end of 2012, eight small molecule tyrosine kinase inhibitors (TKIs) have been approved by State Food and Drug Administration of China for cancer treatment. In this paper, the pharmacokinetic characteristics (absorption, distribution, metabolism and excretion) and drug-drug interactions of the approved TKIs are reviewed. Overall, these TKIs reach their peak plasma concentrations relatively fast; are extensively distributed and highly protein bound (> 90%); are primarily metabolized by CYP3A4; most are heavily influenced by CYP3A4 inhibitors or inducers except for sorafenib; are mainly excreted with feces and only a minor fraction is eliminated with the urine; and are substrate of the efflux transporters ABCB1 (P-gp) and ABCG2 (BCRP). Additionally, many of the TKIs can inhibit some CYP450 enzymes, UGT enzymes, and transporters. Gefitinib, erlotinib, dasatinib, and sunitinib are metabolized to form reactive metabolites capable of covalently binding to biomolecules.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Phenylurea Compounds
/
Pyrimidines
/
Pyrroles
/
Quinazolines
/
Protein-Tyrosine Kinases
/
Pharmacokinetics
/
Glucuronosyltransferase
/
Niacinamide
/
Cytochrome P-450 Enzyme System
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS